• Human Resources
  • Pharmacovigilance
  • Contacts
  • EN
Laboratórios ATRAL
  • Atral
    • Who are we?
    • Mission and values
    • Atral’s News
  • Atral in the World
  • Services
    • Third Party Production Contract (CMDO)
    • Licensing Out
    • Regulatory – Regulatory Affairs
  • Production
    • General Unit
    • Units of Cephalosporins
    • Penicillins Unit
    • Quality control
  • B. Development
    • Business Development
    • Investigation and development
  • Products
    • Medicinal Products Subject to Medical Prescription
    • Medicinal Products Not Subject to Medical Prescription and Food Supplements

Products

Medicinal Products Subject to Medical Prescription

  • Amizal®

    Information leaflet
  • Atralxitina®

    Information leaflet
  • Betamox ES®

    Information leaflet
  • Betamox Plus®

    Information leaflet
  • Biloban®

    Information leaflet
  • Binosto®

    Information leaflet
  • Cefradur®

    Information leaflet
  • Cipamox®

    Information leaflet
  • Ecamais®

    Information leaflet
  • Lentocilin®

    Information leaflet
  • Mirtazapina Psidep®

    Information leaflet
  • Neocef®

    Information leaflet
  • Penicilina Atral

    Information leaflet
  • Zinasen®

    Information leaflet
  • Zotinar Capilar®

    Information leaflet
  • Pharmacovigilance
  • Human Resources
  • Contacts
  • Atral
    • Who are we?
    • Mission and values
    • Atral in the World
  • Services
    • Third Party Production Contract (CMDO)
    • Licensing Out
    • Regulatory – Regulatory Affairs
  • Production
    • General Unit
    • Penicillins Unit
    • Units of Cephalosporins
    • Quality control
  • B. Development
    • Business Development
    • Investigation and development
  • Products
    • Medicinal Products Subject to Medical Prescription
    • Medicinal Products Not Subject to Medical Prescription and Food Supplements
2018 ATRAL. All rights reserved. Made by ActiveMedia
  • Terms of Use
  • Privacy Policy
This website uses cookies to offer you a better experience. For further information, please readTerms of use. OK